ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, the second-generation BCR-ABL inhibitors, dasatinib and nilotinib were developed to overcome this resistance to imatinib, making it possible to treat CML patients with many BCR-ABL gene mutations [19,20].